Maximus Inc designs, develops, and delivers programs enabling people to access vital government services. It translates health and human services public policy into operating models that achieve outcomes for governments at scale. The company covers a broad array of services, including the operation of large health insurance eligibility and enrollment programs; clinical services, including assessments, appeals, and independent medical reviews; and technology services. The company operates through the following segments: U.S. Federal Services, U.S. Services, and Outside the U.S. A majority of its revenue is derived from the U.S. Federal Services segment, which engages with various U.S. federal government agencies to deliver clinical services, maintenance services, and technology solutions.
Last trade$64.46
Day change-$0.945 (-1.44%)
Day range$61.97 – $67.82
Volume215,132
Market cap$3.42B
OpenXNYS
Fundamentals
Key company ratios and reported financial statements.
Source: Massive.com
Key ratios
Valuation
Market capitalization
$3.42B
Price / earnings
9.23×
Price / book
1.97×
Price / sales
0.65×
EV / sales
0.95×
EV / EBITDA
7.01×
Profitability
Earnings per share
$7.08
Return on assets
8.49%
Return on equity
21.31%
Dividend yield
1.99%
Liquidity and leverage
Debt / equity
0.94×
Current ratio
2.42×
Quick ratio
2.42×
Cash ratio
0.08×
Cash flow
Price / cash flow
7.29×
Price / free cash flow
7.9×
Free cash flow
$433.23M
Ratios use trailing-twelve-month financials and market data as of
Nov 16, 2026.
Financial statements
Income and cash flow amounts are for the period; balance sheets are point-in-time
snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are
displayed when available.
Income statement for MMS, quarterly periods
Line item
Q3 FY2026 Jun 30, 2026
Q2 FY2026 Mar 31, 2026
Q1 FY2026 Dec 31, 2025
Q4 FY2025 Sep 30, 2025
Q3 FY2025 Jun 30, 2025
Q2 FY2025 Mar 31, 2025
Q1 FY2025 Dec 31, 2024
Q4 FY2024 Sep 30, 2024
Revenue
$1.28B
$1.31B
$1.35B
$1.32B
$1.35B
$1.36B
$1.4B
$1.32B
Cost of revenue
$930.17M
$963.7M
$1.03B
$984.86M
$988.89M
$1.02B
$1.1B
$1.01B
Gross profit
$348.8M
$342.26M
$318.67M
$333.55M
$359.51M
$338.82M
$301.56M
$301.7M
Selling, general and administrative
$167.19M
$173.48M
$152.16M
$187.68M
$170.83M
$162.86M
$191.74M
$166.9M
Research and development
$0
$0
$0
$0
$0
$0
$0
$0
Total operating expenses
$187.38M
$193.78M
$172.46M
$210.69M
$193.84M
$185.85M
$214.77M
$189.94M
Operating income
$161.43M
$148.49M
$146.21M
$122.86M
$165.67M
$152.97M
$86.79M
$111.76M
Interest expense
-$23.88M
-$22.11M
-$20.82M
-$22.43M
-$22.66M
-$21.47M
-$17.52M
-$20.01M
Income before taxes
$138.16M
$126.53M
$126.27M
$100.47M
$142.97M
$132.46M
$68.95M
$92.67M
Income taxes
$34.57M
$28.47M
$32.32M
$25.18M
$36.99M
$35.89M
$27.76M
$20.17M
Net income
$103.59M
$98.06M
$93.94M
$75.29M
$105.98M
$96.57M
$41.2M
$72.5M
Net income attributable to common shareholders
$103.59M
$98.06M
$93.94M
$75.29M
$105.98M
$96.57M
$41.2M
$72.5M
EBITDA
$193.49M
$181.11M
$179.4M
$160.04M
$198.29M
$185.4M
$118.28M
$144.61M
Basic earnings per share
$1.96
$1.81
$1.71
$1.34
$1.87
$1.70
$0.69
$1.20
Diluted earnings per share
$1.95
$1.80
$1.70
$1.31
$1.86
$1.69
$0.69
$1.18
Recent news
Company coverage with links to the original publishers.
Maximus (MMS) shares gained 15.7% over three months, outperforming its industry. The company is expanding into defense and national security with a $47 billion addressable market, while AI features are included in 75-80% of new bids, contributing to a 3.5-percentage-point margin improvement. The company repurchased $50.4 million in shares in Q3 and projects fiscal 2026 free cash flow of $425-$475 million.
Stantec reported Q3 2026 earnings of $1.35 per share, beating consensus estimates of $1.26, with revenues of $1.33 billion exceeding expectations. However, the stock has declined 20% year-to-date versus the S&P 500's 11.3% gain. The company holds a Zacks Rank #3 (Hold) rating with mixed estimate revisions. Meanwhile, Maximus is expected to report quarterly earnings of $1.88 per share, representing 16.1% year-over-year growth, though revenues are projected to decline 1.8%.
Veralto (VLTO) reported Q2 2026 results with Water Quality sales rising 10.1% year-over-year and Product Quality & Innovation sales gaining 3.8%. The company maintains a solid cash position of $2.12B and generated $328M in free cash flow. Strategic acquisitions expand capabilities in water treatment and quality workflows. However, stiff competition in waste management and limited public-market history present headwinds. VLTO carries a Zacks Rank #3 (Hold) rating.
Maximus, a performance medicine telehealth company, has been ranked #7 on the Financial Times' list of The Americas' Fastest Growing Companies 2026, based on compound annual revenue growth between 2021-2024. The company, founded in 2020, offers online treatments including testosterone optimization, GLP-1 weight loss, and peptide therapies, and is backed by Founders Fund and 8VC.
Maximus has developed a groundbreaking topical oxytocin cream that provides sustained hormone release for up to 12-16 hours through a novel transdermal delivery technology, addressing previous challenges in maintaining therapeutic oxytocin levels.
Dividends
Declared distributions and recorded event dates. Forecasts are not
shown.
Updated daily
No declared upcoming dividend found.
Ex-dividend
Amount / share
Pay date
Type
Nov 13, 2026
$0.33
Nov 30, 2026
recurring
Aug 14, 2026
$0.33
Aug 31, 2026
recurring
May 15, 2026
$0.33
Jun 1, 2026
recurring
Feb 13, 2026
$0.33
Mar 2, 2026
recurring
Nov 14, 2025
$0.30
Dec 1, 2025
recurring
Stock splits
Historical share-structure events and their execution dates.